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Abstract: Timely and accurate diagnosis of myasthenia gravis, particularly in patients with fluctuat-
ing, isolated ocular involvement, remains challenging. Serological antibody testing and repetitive nerve
stimulation of peripheral muscles usually have low sensitivity in these patients. Edrophonium testing
may cause adverse events, single-fiber electromyography (SFEMG) is time-consuming and both tests
are often unavailable outside specialized institutions. Repetitive ocular vestibular evoked myogenic po-
tential (roVEMP) stimulation has recently been introduced to facilitate the diagnosis of myasthenia
gravis. Similar to repetitive nerve stimulation, roVEMPs detect muscle decrements with the benefit of
being non-invasive and allowing for direct measurement of the extraocular muscles. This review summa-
rizes the clinical evidence of the diagnostic value of roVEMP for myasthenia. Prospective clinical trials
have demonstrated high sensitivity and specificity. RoVEMPs are of particular interest in challenging
myasthenia subgroups with isolated ocular involvement, negative serology, and/or negative conventional
electrophysiological results. Optimal roVEMP repetition rates of 20-30 Hz have been identified. This
promising novel diagnostic tool merits further attention and investigation to establish its value as a
clinical test for myasthenia.
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Timely and accurate diagnosis of myasthenia gravis, particularly in patients with
fluctuating, isolated ocular involvement, remains challenging. Serological antibody testing
and repetitive nerve stimulation of peripheral muscles usually have low sensitivity in these
patients. Edrophonium testing may cause adverse events, single-fiber electromyography
(SFEMG) is time-consuming and both tests are often unavailable outside specialized
institutions. Repetitive ocular vestibular evoked myogenic potential (roVEMP) stimulation
has recently been introduced to facilitate the diagnosis of myasthenia gravis. Similar
to repetitive nerve stimulation, roVEMPs detect muscle decrements with the benefit of
being non–invasive and allowing for direct measurement of the extraocular muscles.
This review summarizes the clinical evidence of the diagnostic value of roVEMP for
myasthenia. Prospective clinical trials have demonstrated high sensitivity and specificity.
RoVEMPs are of particular interest in challenging myasthenia subgroups with isolated
ocular involvement, negative serology, and/or negative conventional electrophysiological
results. Optimal roVEMP repetition rates of 20–30Hz have been identified. This promising
novel diagnostic tool merits further attention and investigation to establish its value as a
clinical test for myasthenia.
Keywords: myasthenia gravis diagnosis, electrophysiology, vestibular evoked myogenic potentials, repetitive
nerve stimulation, ocular myasthenia
OCULAR MYASTHENIA GRAVIS – A DIAGNOSTIC CHALLENGE
Ocular myasthenia gravis (OMG) is a rare, but potentially sinister autoimmune condition, that
affects neuromuscular transmission. For various reasons extraocular muscles are particularly
susceptible to transmission deficits at the neuromuscular junction, hence diplopia and/or ptosis
are the initial complaint in up to 75% of patients (1). Progression to a potentially life-threatening
state can occur unexpectedly. In 20–70% of patients, OMG generalizes to involve the peripheral,
bulbar and/or respiratory musculature (2–4). Furthermore, myasthenia gravis can be associated
with thymoma and other autoimmune conditions (5). Hence, early diagnosis and adequate
treatment is of utmost importance. “Fluctuation,” the hallmark of the disease and its clinical
signs, often impedes the diagnostic process. Moreover, serologic antibody testing, as well as
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repetitive nerve stimulation of peripheral muscles is reported to
be less sensitive in OMG as compared to generalized myasthenia
gravis (MG), with sensitivity rates of approximately 50% vs. up
to 90% (6–12). Edrophonium testing may cause fatal adverse
events and is often unavailable outside specialized institutions.
With sensitivity and specificity levels above 85%, single fiber
electromyography (SFEMG) of the orbicularis oculi muscle
currently is the gold standard for the diagnosis of OMG, but it
is time-consuming and examiner dependent (9, 13–15).
So far, several diagnostic methods, mainly using oculographic,
orthoptic and tonographic parameters, have attempted to utilize
eye movement fatigability for the diagnosis of OMG. For various
reasons (availability, reliability, accuracy and difficulties assessing
diplopia due to yoke muscle activation) none of these have
been implemented in clinical practice (16). Repetitive ocular
vestibular evoked myogenic potential (roVEMP) stimulation, as
a non-invasive, non-pharmacological test may have the potential
to fill this gap.
OCULAR VESTIBULAR EVOKED
MYOGENIC POTENTIALS (OVEMPS) -
OVERVIEW AND CLINICAL UTILITY
Ocular vestibular evoked myogenic potentials (oVEMPs)
are biphasic myogenic responses to utricular stimulation
representing crossed vestibulo-ocular reflexes (17). The
oVEMP reflex has been shown to originate from the
inferior oblique muscle and is elicited in response to
otolith stimulation via bone-conducted vibration or air-
conducted sound (18). After activation of the vestibular
nerve and nucleus the oVEMP pathway is thought to travel
through the medial longitudinal fasciculus, oculomotor
nuclei and nerves to reach the extraocular muscles. They
are recorded via surface electrodes from the contralateral
inferior oblique muscle. In recent years oVEMPs have gained
clinical significance, now forming an essential component
of routine neuro-otological workup (19). Their clinical
value lies in allowing for specific assessment of utricular
function. OVEMPs are useful parameters for the diagnosis
of diverse neuro-otological disorders e.g., Menière’s disease,
vestibular neuritis, vestibular Schwannoma or superior
semicircular canal dehiscence (20). OVEMPs are a well-
tolerated, rapid and simple diagnostic method, which




(ROVEMP) AS A NOVEL DIAGNOSTIC TEST
FOR OCULAR MYASTHENIA – A REVIEW
OF THE LITERATURE
Patients with MG typically show a decrementing response to
repetitive nerve stimulation. As mentioned above, in patients
with isolated ocular involvement this characteristic decrement
is often absent in the peripheral musculature. RoVEMP mirrors
repetitive nerve stimulation, but has the key advantages of direct
and non-invasive measurement of the extraocular muscles, along
with exceptionally fast repetition rates.
We performed a literature search in the PubMed and
Medline databases through to April 2020. The search query in
PubMed was phrased as follows: (“ocular myasthenia vestibular
evoked myogenic potentials” [Mesh]) OR (repetitive ocular
vestibular evoked myogenic potentials∗ [Title] AND myasthenia
[Title]) OR (ocular myasthenia [Title] AND VEMP [Title]).
An equipollent search query was used to search the Medline
database. The references in eligible papers identified in the initial
search were also screened. Four original papers of relevance
were identified.
In 2016 Valko et al. published on the first application
of roVEMPs for the diagnosis of ocular myasthenia gravis.
FIGURE 1 | Experimental setup of roVEMP stimulation. The mini-shaker
delivers bone-conducted vibration to the skull. Responses from inferior oblique
extraocular muscles are recorded using surface electrodes (black: active, red:
reference, green: grounding). Reprinted with permission from Wirth et al. (23).
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FIGURE 2 | RoVEMP responses of a myasthenia subject examined with stimulus trains of 30Hz.
Our study included 27 myasthenic patients and 28 healthy
controls. Stimulation with 4ms bursts of 500Hz bone-conducted
skull vibration at repetition rates of 3, 10, and 20Hz were
applied, with 20Hz yielding the most effective results. The
setup for roVEMPs was similar to the standard oVEMP
montage (21, 22). A train of 10 repetitive vibration bursts
were delivered via a shielded hand-held mini-shaker to the
forehead at the hairline in the midline (the skull location
identified as standard AFz’). Responses were acquired using
surface electrodes mounted at the infraorbital margins, with
the reference electrodes directly below and the patient holding
maximal up gaze (Figure 1 RoVEMP setup). This proof-of-
concept study reported sensitivity levels of 89% when a unilateral
decrement (whenever at least one of the two eyes showed a
decrement) and 63% when a bilateral decrement (whenever
both eyes showed a decrement) was considered. Specificity levels
were 64% (for unilateral decrement) and 100% (for bilateral
decrement) (24).
In 2018 El-Sayed Mojahed et al. studied whether oVEMP
stimulation (without repetitive stimulation) allows for
differentiation between healthy controls and various myasthenia
subgroups (25). In their prospective study, the authors used
air conducted oVEMP stimulation to examine a treatment
naïve myasthenia group (n = 10), a symptomatic myasthenia
group on treatment (n = 15) and an asymptomatic, treatment-
controlled myasthenia group (n = 15) vs. healthy controls
(n = 10). The authors found a significant difference of oVEMP
response rate between healthy controls and myasthenia
subjects (p = 0.002; p = 0.001); however no difference
between the various myasthenia subgroups (p = 0.895)
and when comparing ocular vs. generalized myasthenia
patients (p = 0.895) was found. In conclusion, they state, that
oVEMPs are a useful diagnostic parameter, yet have no value in
differentiating various myasthenic subgroups or in monitoring
therapeutic response.
In 2019 our group published another study with the
purpose of optimizing the stimulation parameters of roVEMP.
18MG patients and 20 healthy controls underwent testing
for this study. A heterogeneous group of MG patients,
of whom 44% reported isolated ocular symptoms, 22%
bulbar weakness and 50% generalized muscle weakness, were
included. Fourteen patients were on treatment at the time
of testing. The experimental setup was similar to the initial
description of our group in 2016 (24). We found that
repetitive stimulation at 30Hz resulted in highest sensitivity
and specificity values, whereby repetition rates at 20, 40,
and 50Hz also led to a robust decrement in the inferior
oblique muscles of myasthenia patients (23). (Figure 2 Single
patient RoVEMP result at 30Hz) When using the smaller
decrement of the two tested eyes 30Hz repetitive stimulation
resulted in sensitivity and specificity values of 71 and 94%
(area under the curve (AUC) 0.88) and 82% sensitivity and
78% specificity when considering the larger decrement for
analysis (AUC 0.81) [Figure 3 Results with ROC curves of
30Hz repetitive stimulation, modified and reprinted with
permission (23)] Recordings from the inferior oblique muscle
were superior to recordings from the lateral rectus muscles
and continuous 100Hz stimulation was not found to be
useful for the differentiation between diseased participants and
healthy controls.
A recent prospective case-control study examined whether
roVEMP allows for differentiation of MG from relevant
differential diagnoses, such as Lambert-Eaton myasthenic
syndrome (LEMS), genetically confirmed congenital myasthenic
syndrome, inclusion-body myositis, facioscapulohumeral
muscular dystrophy, myotonic dystrophy, myopathy,
oculopharyngeal muscular dystrophy (OPMD), chronic
inflammatory demyelinating polyneuropathy, cranial nerve
palsies (III, IV, VI), mechanical diplopia, and Graves’
orbitopathy (GO) (26). The study included 92MG patients,
22 healthy controls, 33 patients with a neuromuscular disease
other than MG (as mentioned above), 4 LEMS patients
and 2 congenital myasthenic syndrome patients. Results
showed a significantly larger decrement in MG patients
(28.4% ± 32.2) as compared to healthy controls (3.2%
± 13.9; p < 0.001) and neuromuscular controls (3.8%
± 26.9; p < 0.001). When considering neuromuscular
controls as reference, roVEMPs resulted in a sensitivity
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FIGURE 3 | Receiver operating characteristic curve (ROC) statistics for optimal cut-off determination. Box plots in panels (A,B) compare the distribution of
participants and show data of the 30Hz paradigm. The dashed red lines indicate the optimal diagnostic thresholds for eyes with the larger decrement, i.e., unilateral
(A) and for eyes with the smaller decrement, i.e., bilateral (B), as derived from the red ROC curves shown in panels (C,D). Area under the curve (AUC) was largest
using 30Hz trains (red). Modified and reprinted with permission from Wirth et al. (23).
of 67% and a specificity of 82%. The mean decrement in
ocular MG (32.1% ± 23.7) and generalized MG patients
(27.1% ± 34.9) was comparable. A subgroup analysis of
seronegative (Acetylcholine receptor antibody) and SFEMG




Current literature suggests that roVEMPmay serve as a valuable,
well-tolerated and inexpensive test for the diagnosis of MG.
The vibration bursts used for bone-conducted oVEMP allow
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for stimulation at high repetition rates to drive the response of
the small extraocular motor units into a decrement. Based on
this unique property, roVEMP stimulation represents an ideal
examination technique for detecting a decrement in extraocular
muscles. This facilitates the diagnosis of seronegative and SFEMG
negative ocular myasthenia, the most challenging subgroup of
patients. RoVEMP stimulation has been proven useful in a
number of clinical studies. Data suggest its value in distinguishing
MG from other rare neuromuscular and ophthalmic diseases (i.e.,
LEMS, OPMD, GO etc.) and its usefulness in generalized MG.
Although usually clinically distinguishable, it is not yet
clear, whether roVEMPs are also capable of differentiating
other causes of ptosis (e.g., involutional/aponeurotic, congenital,
ptosis in the context of Horner’s syndrome) and diplopia
(e.g., supranuclear palsies, mitochondrial myopathies, Duane’s
syndrome, strabismus etc.) from MG. Moreover, there are
currently limited data about the utility of roVEMP in additional
MG subgroups (e.g., patients on immunomodulatory treatment
vs. treatment- naïve patients, patients post thymectomy etc.).
Further prospective studies are warranted to establish the
definitive value of roVEMP in clinical practice.
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